why choose us

First received: May 18, 2023

Clinical Trial: A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloid Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia

Brief Summary: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

Read more